{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.2",
    "document_metadata": {
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "Private Ownership to Fraunhofer Institute SCAI",
      "contact": "farah.humayun@scai-extern.fraunhofer.de",
      "name": "heme_26875449.bel",
      "version": "1.0.2",
      "authors": "Farah Humayun",
      "description": "Heme BEL model is a disease model based on Biological Expression Language (BEL) containing the core mechanisms of heme as modulator in Hemolytic diseases such as sickle-cell anemia, beta-thalassemia, malaria and autoimmune hemolytic anemia."
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns",
      "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$",
      "PUBCHEM": "^\\d+$",
      "HM": ".*"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": ".*",
      "TimePoint": ".*",
      "Concentration": ".*"
    },
    "annotation_list": {},
    "path": "c:\\users\\syedf\\pycharmprojects\\heme\\curation\\heme_knowledge\\heme_26875449.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "heme",
      "id": "719ca721f83fc39055585fbe7f31ad8173f7538a3cfa3792732de47c43a36048e922aa16d66b08e964b7d4a89e214d0d313bce30a38fe67755b9428cdec247cc",
      "bel": "a(CHEBI:heme)"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "hemin",
      "id": "1a5539813113f4756705ebef4b6b2d9231a850264f80d4b58dfdb2ca21c217de46c6eace3a1750835bc3f6d9d9997d99396983f3a5f1d0369a8532a78cac3c82",
      "bel": "a(CHEBI:hemin)"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "thioester",
      "id": "e35a08d762bd7b6d1e04e12bc3e6fce283a0c2f0c4829aef828d9f291a8a8fcebe37f60aeb3545ea4417f82bf2d9d5ed5f4756ba046bc8deebe73a37ef9f0c42",
      "bel": "a(CHEBI:thioester)"
    },
    {
      "function": "Abundance",
      "namespace": "HM",
      "name": "Complement C3b deposition",
      "id": "270473dbd7c9d25be3230656de66144840455a050122b4665b80a9fbd545a05bbf362b9b4abfa34c78d391250bbc28f70aaf7249d58d919e3d750b28b61e969a",
      "bel": "a(HM:\"Complement C3b deposition\")"
    },
    {
      "function": "Abundance",
      "namespace": "HM",
      "name": "Complement C3dg deposition",
      "id": "ea77840249bee641e45377f2aba6a016e1f16cadd025eb89b8b2f5b0ad6d1cd4b2e6f6a1f97023afa7d190f34e38045c7f8562d4c7e213c3e15cbe59c2884045",
      "bel": "a(HM:\"Complement C3dg deposition\")"
    },
    {
      "function": "Abundance",
      "namespace": "HM",
      "name": "Complement iC3b deposition",
      "id": "e7aa63b902a9c637972161320756ecb764c4560d3bece4664183e3d5f9fdc882f8f801e48d264ac59d45627f81c698f7d530c1e5bbb3b9ee6b153c7fa87509cc",
      "bel": "a(HM:\"Complement iC3b deposition\")"
    },
    {
      "function": "Abundance",
      "namespace": "HM",
      "name": "Weibel–Palade bodies degranulation",
      "id": "08be3aeccdadbadcfa9109e0646a52396c04d7bffd1723badecfb2166a933261047eabe432841a11961576f46e3d3585984fd02f2c789f7e3c3d79c92a4f2dab",
      "bel": "a(HM:\"Weibel–Palade bodies degranulation\")"
    },
    {
      "function": "Abundance",
      "namespace": "HM",
      "name": "oxidative reactions",
      "id": "424bc8c5ee95b5a9ac077c96ec0fdd63901bb2f7bd11a22842ae879e021f4b04cae5a4564feea644a1e45a1220947f7269f7b5cb8b6ff9347c965f4a9fd7dcf6",
      "bel": "a(HM:\"oxidative reactions\")"
    },
    {
      "function": "Abundance",
      "namespace": "HM",
      "name": "erythrophagocytosis",
      "id": "bac9c07789a564cc366314aee9e3a2c1d62636dbb4c02865888c17574fb21a30c65181203ab5f20993830f9d209274452d01a13f29ab8f1230ed5dc956fa262f",
      "bel": "a(HM:erythrophagocytosis)"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Cell-Derived Microparticles",
      "id": "cbdd1c0e96832ed2dc8166dd4de0db4724d8bf06ba0c5e7b8f6720cf04d7c50fcf8abc5cc8cc27228f47b8b422592d1084bb0e832c29fb932d57b70741c4413d",
      "bel": "a(MESH:\"Cell-Derived Microparticles\")"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Complement C3a",
      "id": "572d4205a3417e5f5a92b8ae26e580b597fcfab4201abe34f539500bc64785bb3aafe6edfbfe1235a144e7ea990225571a4360eebb4b5c914c7b9add87a7bf89",
      "bel": "a(MESH:\"Complement C3a\")"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Complement C5a",
      "id": "41c64b39e6217a0c85c123e780f83595146ef1afc36f1d2ba0b8e2c27edd3b86f8f21c00e1e1dfdc01000353bdf826feaa871b1823a750e63821b2138cea9ab5",
      "bel": "a(MESH:\"Complement C5a\")"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Complement Membrane Attack Complex",
      "id": "697440f9efe6d464dff14ff66b2554c4c0fac81fd532f4039c33a96b1070ad6aaf25f4b64023470df259819a994b8fae792ef76b64d97ef8d38de60855f16b0b",
      "bel": "a(MESH:\"Complement Membrane Attack Complex\")"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Toxic Actions",
      "id": "d0a77d591b79dc5af5bab6bc54a49ce4867bb868f3c9347334883a9f831c648df14b300bef4cc0ccb7c3b10c81713d29f61a1bd720a71a4117679f3c9047ed90",
      "bel": "a(MESH:\"Toxic Actions\")"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Fibrin",
      "id": "dcd81fb34ae1e9c14e11e108f1e34383f107c53e2c2468ae6d3da1aa4f3f03cbc2d081599412a863f5afe0ca8f9318f9de412ce3893a7a5b4b7eb164be17cc1e",
      "bel": "a(MESH:Fibrin)"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Plasmodium",
      "id": "a4ff374be4afed35a01192d4217d67fc0b930fbae629be184802159e00e4cbdc7ef96c363c70182eb8b2e537de794df16262dbd133527e172427df78540bc59c",
      "bel": "a(MESH:Plasmodium)"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "blood coagulation, extrinsic pathway",
      "id": "6b7032cef83f00d90e1e1bf09fda13a7953dbcfe42a0d03eed47dc0e29f70af513a2fa7b9500ae1961a985c466d89e0ffc09a1b745302073e277cdb405193c85",
      "bel": "bp(GO:\"blood coagulation, extrinsic pathway\")"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "complement activation",
      "id": "7dffe42517c3d74ef8db1b8f29a0be191ff33eb743bcb3f274446e3e4e0af75347a0294e3d14b50508fa8f0e46b076f844f664d7f93566c31246a2f841df1316",
      "bel": "bp(GO:\"complement activation\")"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "complement activation, alternative pathway",
      "id": "1ce263917e71ed0c37c9cec08dc3ff15ec5234515006e1a44b39911fceab5f568becf73c72bd66de7246f4936ddc9f5d4160ed133ff6d59bc9eb41f068d863ea",
      "bel": "bp(GO:\"complement activation, alternative pathway\")"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "complement activation, classical pathway",
      "id": "9329f4cea3f0e5acb9c9d88b3153f23590a094aea9949f8457f580fbee216792ff451a5ac8ea8ac163b95107d117d403cc38e982765500613eb0d186e7fe70f0",
      "bel": "bp(GO:\"complement activation, classical pathway\")"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "endothelial cell activation",
      "id": "c894e9d33edfed940a51b6b3c296739792fd65fa6d722a79d7adc2bb71d574d2b29d8567e118c9c88d2447f6fd8b362ac1ae9361950533cd5069ee34104f7689",
      "bel": "bp(GO:\"endothelial cell activation\")"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "neutrophil activation",
      "id": "e30fc31dd56009c9ff9eafa73c6fd5daac54e234231794745a4fa11600d2a00f772e830fde93aa7bc07d138531018372f1891bac6583a0d224da1fd49b12957f",
      "bel": "bp(GO:\"neutrophil activation\")"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "platelet activation",
      "id": "668939e1a7166202876f21af69bbe8367e08002ac69312d1326c46aa605b22c0fffb3c9f2cd1073782f79141c51903b9e898140df4deda6e150565e6ad25babb",
      "bel": "bp(GO:\"platelet activation\")"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Antibody Specificity",
      "id": "aca855319c622e5f04d11fe427a8577d37c37108fe16f6d5b8b72a7c8065909633449dc6626d5e4d5cef2747ca157fe0fc377f32132dd6cd79b90a4fa452bd40",
      "bel": "bp(MESH:\"Antibody Specificity\")"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Erythrocyte Count",
      "id": "9ad455e5601363a918f538de6c61f2550ff91e96f6021087a83a88d0346c89c09b78f4e1fa43ca523a6c32aa7bd3804685a5790ceb767f729994633627ef24d6",
      "bel": "bp(MESH:\"Erythrocyte Count\")"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Erythrocyte Deformability",
      "id": "aafe5f8fc07e6abe467e9e2c47e0be8c08012664bc30134675ce5df8b3ab3ccc93ed0cdec5627fb8e8ab4f5e2cc991a6fb0ce0adfe41fe8358ea8c37ac60816d",
      "bel": "bp(MESH:\"Erythrocyte Deformability\")"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Oxidative Stress",
      "id": "32bd3ab5e8a3a26be3209856c88741f0f0e2dff98d2587599a6a21b0f4793c5d8feb1194ea2166cf3cece076e7095530b116270e6655bc8feb35a437fda42cf6",
      "bel": "bp(MESH:\"Oxidative Stress\")"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Platelet Aggregation",
      "id": "026950aa67d966b0562d40da4c1a06acbb77aacf83d7fd29ac0f546d1cf200c9c4f588431ca9e719d2bdc1c8ed8962fdf947ffad69d21bbdccd0362f529ef5bf",
      "bel": "bp(MESH:\"Platelet Aggregation\")"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "MESH",
      "name": "Eryptosis",
      "id": "ffbf53403f946cfd9921d613f7acf5d1eaa8bfbef19b2e41549c17b09bebc9a91596a261988e5e713c51594a9a2084324a6fe2c2adb7a78954b510ae93630e93",
      "bel": "bp(MESH:Eryptosis)"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "heme",
          "id": "719ca721f83fc39055585fbe7f31ad8173f7538a3cfa3792732de47c43a36048e922aa16d66b08e964b7d4a89e214d0d313bce30a38fe67755b9428cdec247cc",
          "bel": "a(CHEBI:heme)"
        },
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "thioester",
          "id": "e35a08d762bd7b6d1e04e12bc3e6fce283a0c2f0c4829aef828d9f291a8a8fcebe37f60aeb3545ea4417f82bf2d9d5ed5f4756ba046bc8deebe73a37ef9f0c42",
          "bel": "a(CHEBI:thioester)"
        }
      ],
      "id": "e752f1434483fc3dc229ecc82ac87f273ef5316db4f75080c9d346f04e0f2e00037b01f1862e183ff44a045d7f1d19fce08156c22090ca7f0ae70466e1fc1b2b",
      "bel": "complex(a(CHEBI:heme), a(CHEBI:thioester))"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "heme",
          "id": "719ca721f83fc39055585fbe7f31ad8173f7538a3cfa3792732de47c43a36048e922aa16d66b08e964b7d4a89e214d0d313bce30a38fe67755b9428cdec247cc",
          "bel": "a(CHEBI:heme)"
        },
        {
          "function": "Protein",
          "namespace": "PFAM",
          "name": "C1q",
          "id": "be4b9b6438aed3835f58a0dccaee333fd2ec388a51081301a3bcbdf7209d1f95264638fcc6175dd722cfdb139354c6300fa4d1ee6996ce3c9b8f52e143d0e753",
          "bel": "p(PFAM:C1q)"
        }
      ],
      "id": "138c0f8c636e977d097b69401c576179f6730c77b861e02d2b1631355b4edc3ddb04b4537322a3f4b8eee25419bacc55d78f7675943eafd04a56f07238c4ef8f",
      "bel": "complex(a(CHEBI:heme), p(PFAM:C1q))"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "F3",
          "id": "afb1d311045b4ee19a7d907dc8dd92023621887d3c4f0e75bad2a18fce0ef6a80cdfde64fe2c3c0504f5bbd1588964fd173eff33d4da51d1ddd156588943ea10",
          "bel": "p(HGNC:F3)"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "F7",
          "id": "01f772db5966ef76162a35421c3f42c3e1c55a07259a7675d3da2ea1052b5e2c02b07093392c7d9c936456602448f0d0d9c7a25e9852ccc24fc089bec091fcf8",
          "bel": "p(HGNC:F7)"
        }
      ],
      "id": "ec0cd0dddd8fbd0d4f46d00c6cc7f0cc790dbbed132e3ec164d053d7f2afb78a85ba6e101a8c7251ec64f41bd7b8bae7a04e812412ce2a5d92aa06e5c9a4eefb",
      "bel": "complex(p(HGNC:F3), p(HGNC:F7))"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "AMBP",
      "id": "0b37d3c803f2d3c4918b4a254f486462ee5463ebf252e088a50a228332537b2d84e8c9bb1089a9b40a9c5730af5bf8de5574c7f3391b5de4f28b518acb1bdd79",
      "bel": "p(HGNC:AMBP)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "C3",
      "id": "0edfd55c060706048fdcf977108c333ff8efc8adbf002b1c9dde5c3bd1dcc787db0397fd423224707a5e691d14afdb25dba7beaabd44b15dc8dff5d21c5034c5",
      "bel": "p(HGNC:C3)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CD46",
      "id": "da10fce165d2908b0004a3936e912eabb32c52af1bcaa6fb4b350647b6efaaa12768b36226dbcc064ce922e568ed131a0fbc5236f12ac4559ab4fcdbd22d95c3",
      "bel": "p(HGNC:CD46)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CD55",
      "id": "582341a6d212dede0879e274bf35b572fd11d01869b232ecd0426f2f93d9b142081321dd2b13af5abbb81cc3de472cb1ae18259523e166abb9b445558b7dea26",
      "bel": "p(HGNC:CD55)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CD59",
      "id": "cc68931776a96853d13400a3a86c2a80fc8cc18b08584c410f48699c1a202ee0f66b699f5b7be2ccdf818749bf0f3a92f3fb51d60138ead3aed23e5de2f3b992",
      "bel": "p(HGNC:CD59)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CFB",
      "id": "0c9d03749fe16696fcde4c187d99a33c66cac139ae2afdfed65c1a6ba451c9a59faa69e088f8e0135400cb538d13443124ed7fcb9c173d25dee7b11348288bf9",
      "bel": "p(HGNC:CFB)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CFD",
      "id": "1fedd55598e0a311e83f1345b39128739ad616ec395579c37d0d8e0d9b2d9d793d9d3cb03dff44a27e81436a41f5fbd81aac8cb3753f65294c04aa86ee225da8",
      "bel": "p(HGNC:CFD)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "CFH",
      "id": "fc7eadb98840a209ec88e805b2165b4815f7d4408620a0f92fb74c929fb011a51bba58249ab92ed96529213c91f569713f3d62f6e1023484cfdec738def2efbf",
      "bel": "p(HGNC:CFH)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "F10",
      "id": "75363b2ac5e5b9ec2e5764ebe3bc445452f6fbbf383bbfd3ee1837f9cf128ca3b02389c655de02a6baf047f024af5a9c494378f41a768228c4cef426533f7632",
      "bel": "p(HGNC:F10)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "F3",
      "id": "afb1d311045b4ee19a7d907dc8dd92023621887d3c4f0e75bad2a18fce0ef6a80cdfde64fe2c3c0504f5bbd1588964fd173eff33d4da51d1ddd156588943ea10",
      "bel": "p(HGNC:F3)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "F5",
      "id": "822dda9562a81cb0198212666111f145454c0485f2f7460bcdfc2e8ebcf5e0321e8a440058a1048267c5c156b1d1083001b741598f45a4648d0c0d3bf45bd804",
      "bel": "p(HGNC:F5)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "F7",
      "id": "01f772db5966ef76162a35421c3f42c3e1c55a07259a7675d3da2ea1052b5e2c02b07093392c7d9c936456602448f0d0d9c7a25e9852ccc24fc089bec091fcf8",
      "bel": "p(HGNC:F7)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "F8",
      "id": "0216cc5c0ff3fd797dbe73bdfdce51a3f6aec5c27431b622c38aad035b65d33b9258f2e4ae4ed517a1be16c6f0bf9b57d11afb7d5da7d3e799ec9eb707a2fcc6",
      "bel": "p(HGNC:F8)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "HBB",
      "id": "75606239f93ac271516eb110566907523dfdbf0a1937760050e049e79942bd684a190c3dd54b45444c2c5b5217192e72df697c824cbb392f90f2fa4005d9adb1",
      "bel": "p(HGNC:HBB)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "HMOX1",
      "id": "c4981e9d3903b58471e749e0a1e38277c2729152c5582926243649d5c266ea44d831061cf916b7c6334634d357628b16c015a7ce07c97084f06b2c3f3cc94d5c",
      "bel": "p(HGNC:HMOX1)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "HP",
      "id": "0052c8eac45d6228dca9f6db302e8c98c9d2292c20e1bf791ca8fd0749fa28c163d424e0faa9a8dfa46a882f85d0967fc41819b18763a7abd987d07b8cbec1c3",
      "bel": "p(HGNC:HP)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "HPX",
      "id": "903fb55a7cb538b12d22305b73d01f90a340e7fd5622711c4b41d1538af80cbb1ed5bc2f065f360c8bdc8d377993c9b55bd06633323591ed22f54741612c3775",
      "bel": "p(HGNC:HPX)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "NLRP3",
      "id": "1758ad4da211678a6e4ed0bafd0054a554f7d286651184c3bdfc6ba70f3caa446607d0164b8108f861e90b975dcef41b64619249b61e818b768f09843f0ba11f",
      "bel": "p(HGNC:NLRP3)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "SELP",
      "id": "bd5c153eb5d509c9625e8e411ed47f1126e086926419bd53ac17b8a9eba27358ca66e6ba73e64e8cf64c1efda1f0c102d24fce7bffdb63ca54285a2587e9ea9b",
      "bel": "p(HGNC:SELP)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TLR4",
      "id": "78baff0fa37f42a32cb911fcb85a347d217c0cb39fc58b19343a2a831d87febb268c4e159670cd621d3a7e29526bc3acfb79ac387aadea33a00624d7024e6701",
      "bel": "p(HGNC:TLR4)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TNF",
      "id": "a262f5edbfb734dd0ec9696a3b78644fccfb4054a9cf9225beb17c33ef416a75809ff59ec1646e29a3cccc804c9294f8d2c48120af9f5ee98e764a584626426d",
      "bel": "p(HGNC:TNF)"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "VWF",
      "id": "a101326bdf4988f866703f8a046ed20135ce76b47556ae1a0d5115a2230c7ab01b24d5a03535ec845085d65a60f2bae4b5ddd906244da261baad9420efcb8a10",
      "bel": "p(HGNC:VWF)"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "F3",
      "id": "d6eb2ca4a1bef2c702bbe730d5f99aa68a4b1085f6d7578b9aa13fed1d07b578ff54f988e52ef4ad90f4d7facd905e048b24791d9e3a5fde18ffe0a8beeebeac",
      "bel": "p(MGI:F3)"
    },
    {
      "function": "Protein",
      "namespace": "PFAM",
      "name": "C1q",
      "id": "be4b9b6438aed3835f58a0dccaee333fd2ec388a51081301a3bcbdf7209d1f95264638fcc6175dd722cfdb139354c6300fa4d1ee6996ce3c9b8f52e143d0e753",
      "bel": "p(PFAM:C1q)"
    },
    {
      "function": "Pathology",
      "namespace": "HM",
      "name": "Thrombotic microangiopathy",
      "id": "32014b92fcf4b182b8786bab590465e786654c63603a3fc31908df6867fdc1527e12634ddb6e9db3abe68cccdd8a421cdf61fc70abd746f567e5828645207c27",
      "bel": "path(HM:\"Thrombotic microangiopathy\")"
    },
    {
      "function": "Pathology",
      "namespace": "HM",
      "name": "vaso-occlusive crisis",
      "id": "7007ee304406d4320c9dcbefa93caf0b8ca48c68e148031ff1268674b1581667e2815de7ed2d14f5ac673c886c0493c40b8b821f94db58cf6f8ac9093dca5a48",
      "bel": "path(HM:\"vaso-occlusive crisis\")"
    },
    {
      "function": "Pathology",
      "namespace": "HP",
      "name": "Paroxysmal nocturnal hemoglobinuria",
      "id": "b435a1d59be1cdaa0b4ed194d90883cdd83744b9266a0dfabcd67b3b3602ac6e83e987e8037ee732aa09bf34ebca2af45464d443827dd1d6b2f249563b69e007",
      "bel": "path(HP:\"Paroxysmal nocturnal hemoglobinuria\")"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Acute Kidney Injury",
      "id": "ceb5d050086a580ed32495afbc5cf4c4ce723f0ea5ef95dd84871b5872a9f6ef15e59ad7ca9c102b3571006fef03926e656ebc78e07934b1ab539c8d5d6b7b90",
      "bel": "path(MESH:\"Acute Kidney Injury\")"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Vascular System Injuries",
      "id": "2c1dc10562090ab803cf25bbb0eaa83a64b75c8750bd549df2e66f6f3545a54bd009fd5c1a689c5489abb49876de701c8542c0c371e00e4420f455faa8fff57a",
      "bel": "path(MESH:\"Vascular System Injuries\")"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Atherosclerosis",
      "id": "18fdde6cb24c9d4214eeebf2aa06f1137477ccfb0b31f46c6aab8020e5c4c9787a0d193d08631001c015c81f4f49a5372064be5fd1f4da59ef8653cbe6333b14",
      "bel": "path(MESH:Atherosclerosis)"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Hemolysis",
      "id": "7cfbd58cfcd389d302278ecd54992b3d6039896ac077344c4c47bcafd5379ca16ef441da8e1f3105595a30c4dd7331ca2a6f864432425107f7850f8dbe210b09",
      "bel": "path(MESH:Hemolysis)"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Inflammation",
      "id": "3196cc4c6a20279c822cae925a9b271d0224f2c8d468e3069a3ee460662be286b61db2f144c550686a9c624e58af4ffa7570f4f2384e1cb8ee40496f8cb3fa5e",
      "bel": "path(MESH:Inflammation)"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Malaria",
      "id": "6b20b7391c3b35f2b029a5af26e188cba4855d5b8cf0f88547f6d679928d738f03c46b5b6f289877f0f8c5fb28fd0f4c6cac5bfe3d8830375260b1eceae968c5",
      "bel": "path(MESH:Malaria)"
    }
  ],
  "links": [
    {
      "line": 93,
      "relation": "positiveCorrelation",
      "evidence": "In cases of congenital hemoglobinopathies such as sickle cell disease, deficiencies in complement system regulators such as paroxysmal nocturnal hemoglobinuria, and many other disorders, erythrocytes can lyse and liberate large quantities of hemoglobin.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 58,
      "target": 45,
      "key": "1e13c4010d1b3071ffac05ba997c1dcb7ecb0289975e365c909eb3f4fbe6bd79d1d457da7c40240ac820ebea8c2f75d7aa3c7315bbc5fbb1a18f36a68a120f01"
    },
    {
      "line": 93,
      "relation": "positiveCorrelation",
      "evidence": "In cases of congenital hemoglobinopathies such as sickle cell disease, deficiencies in complement system regulators such as paroxysmal nocturnal hemoglobinuria, and many other disorders, erythrocytes can lyse and liberate large quantities of hemoglobin.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 45,
      "target": 58,
      "key": "0691941edc0617c17d4bf890dedfcfd6849a05bfe7ad8f55f52e8a93bfd2446089fd991a906457b0dd5f0f609d7ebe37fd0e4666fcb2430fbb4fdf55c3d7d392"
    },
    {
      "line": 99,
      "relation": "increases",
      "evidence": "Extracellular hemoglobin and heme are pro-oxidative, proinflammatory, and cytotoxic [10–12], and can contribute to the pathology of hemolytic diseases.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 45,
      "target": 7,
      "key": "e60497d9ca75857d607a549aac857134095eae530b1e4cfcd3f6495d2acfa4db05afd7284689279daa0bd313425472323a4426862b68b18af2144c00bd7b3833"
    },
    {
      "line": 100,
      "relation": "increases",
      "evidence": "Extracellular hemoglobin and heme are pro-oxidative, proinflammatory, and cytotoxic [10–12], and can contribute to the pathology of hemolytic diseases.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 45,
      "target": 63,
      "key": "57d6e33a0f042a8ff3d07a9a0eb18c72eea67cf1562b821b441021bdf7281644c10ad8dfc216084f26bf403407b5f676e792352f0984dc2f8bdf6710b734d88e"
    },
    {
      "line": 101,
      "relation": "increases",
      "evidence": "Extracellular hemoglobin and heme are pro-oxidative, proinflammatory, and cytotoxic [10–12], and can contribute to the pathology of hemolytic diseases.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 45,
      "target": 13,
      "key": "c78474f2b9e53d6653e7018b5b0ff30ec480616b1ae0838d213051c81fbf7948f28e92d093b833fbd1ba31d42c6c48243dab1841b5be2478ce9501b9956725a0"
    },
    {
      "line": 102,
      "relation": "increases",
      "evidence": "Extracellular hemoglobin and heme are pro-oxidative, proinflammatory, and cytotoxic [10–12], and can contribute to the pathology of hemolytic diseases.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 0,
      "target": 7,
      "key": "29ef3b7dc6908a4f64647b46abb4d2e8bac6b2702454991b1ac43c14dab527c457d089ef39d05a8b5f2d6c6f8838607a9b9bf1411879c35e5e2d7460e05c7d0c"
    },
    {
      "line": 103,
      "relation": "increases",
      "evidence": "Extracellular hemoglobin and heme are pro-oxidative, proinflammatory, and cytotoxic [10–12], and can contribute to the pathology of hemolytic diseases.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 0,
      "target": 63,
      "key": "26676cf9bda12f4a6331de98960fd133ed5ab8cc99a324fdb723989ff4cf51f67b42ba4388cd2d5d60dbcf7c90b11101d176359858420088f25c649978789dac"
    },
    {
      "line": 104,
      "relation": "increases",
      "evidence": "Extracellular hemoglobin and heme are pro-oxidative, proinflammatory, and cytotoxic [10–12], and can contribute to the pathology of hemolytic diseases.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 0,
      "target": 13,
      "key": "f787617a4fed7ff29707e32618b981c002057d5db39156000082361fa1893905ab2f5e990c6c42ce49a03d769ebbeaad45037a772f292cf7563c7298ce38c561"
    },
    {
      "line": 138,
      "relation": "increases",
      "evidence": "Most studies concerning the pathophysiological roles of heme have focused on the protective effect of the heme-degrading enzyme, heme oxygenase 1 (HO-1) [25] (Box 2), and on the effect of this danger-associated molecule on cells, leading to oxidative stress, TLR4 signaling [26,27], and NLRP3 inflammasome activation [28] (Box 4).",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 0,
      "target": 26,
      "key": "37d623dbdc7e1d9e23533b8fd3f3aa26c999f557cc972c7bce0f0b91f3f3fe60ff4ab9926988d196ddf630d967f490beb7563d78adbc6dfcbe91820c2c4a5503"
    },
    {
      "line": 139,
      "relation": "increases",
      "evidence": "Most studies concerning the pathophysiological roles of heme have focused on the protective effect of the heme-degrading enzyme, heme oxygenase 1 (HO-1) [25] (Box 2), and on the effect of this danger-associated molecule on cells, leading to oxidative stress, TLR4 signaling [26,27], and NLRP3 inflammasome activation [28] (Box 4).",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 0,
      "target": 49,
      "key": "fdf4aacc9cb31e91e5276271a5aef60418d53c97d040bc16ec077d3082c0ed084a4a7891db437d0dd44a9c01140b923bf705820921a22dff01bd407043aaa1b9"
    },
    {
      "line": 140,
      "relation": "increases",
      "evidence": "Most studies concerning the pathophysiological roles of heme have focused on the protective effect of the heme-degrading enzyme, heme oxygenase 1 (HO-1) [25] (Box 2), and on the effect of this danger-associated molecule on cells, leading to oxidative stress, TLR4 signaling [26,27], and NLRP3 inflammasome activation [28] (Box 4).",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 0,
      "target": 51,
      "key": "31e5bd8be2cfc67df5790bcca74750f44a5384a27d2e9e849aa7703625cc52fc18cb7eeb25c18a3fb3340b88ad1dadbe1b32b0b353699c38d21e6aa4be0658cc"
    },
    {
      "line": 147,
      "relation": "increases",
      "evidence": "For example, one of the severe complications of sickle-cell disease is vaso-occlusion, an outcome that can be triggered in mice upon heme administration [27,32].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 57,
      "key": "c12fb3ba16f4ab75d282f4f10d0a243f95ddfb0969cd02c9a0cdeca8a3f8058b234471ad913c7a850d567de35833723952f07fc374b413e56b72aea01d4db551"
    },
    {
      "line": 155,
      "relation": "increases",
      "evidence": "Heme is one of the factors capable of inducing stimulation and damage of endothelium, promoting the recruitment of neutrophils and sickle-cell erythro- cytes, and subsequently prompting a vaso-occlusive crisis.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 57,
      "key": "1969202b1f6671b04267f358f0865034fe1b615f02f33cc9597056a22670d47b74e716e05e856d10e3e04e8fe341a96d618302e35fb42b52885004587efea5f8"
    },
    {
      "line": 358,
      "relation": "increases",
      "evidence": "Heme may be implicated and contribute to the development of (i) thrombotic microangiopthy in patients with aHUS [33], (ii) vaso-occlusion in sickle-cell disease [18,24,27,32], (iii) vascular injury and kidney dysfunction in transfusion of old blood [16], (iv) atherosclerosis [92], or (v) erythrocyte loss in malaria [77].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        },
        "Cell": {
          "endothelial cell": true
        },
        "MeSHAnatomy": {
          "Serum": true
        }
      },
      "source": 0,
      "target": 57,
      "key": "71de93ab1f6813caaf322d3f4123de25e9b4a04c4bc390f9942eab2c41749b19dd4e6c74a8e176cd3b372f534ce73330076789d7d2c8c786ee14ae845aadb46e"
    },
    {
      "line": 153,
      "relation": "increases",
      "evidence": "Heme is one of the factors capable of inducing stimulation and damage of endothelium, promoting the recruitment of neutrophils and sickle-cell erythro- cytes, and subsequently prompting a vaso-occlusive crisis.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 20,
      "key": "d871b7e296f7be7eee2d6a407f70bfdf2067c6864dec5f67427e289df231346dd79f2c6b56ec7971b09409d8a9f7c1e6aca218c4654b4c2a449dd4308ca284e9"
    },
    {
      "line": 154,
      "relation": "increases",
      "evidence": "Heme is one of the factors capable of inducing stimulation and damage of endothelium, promoting the recruitment of neutrophils and sickle-cell erythro- cytes, and subsequently prompting a vaso-occlusive crisis.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 21,
      "key": "e79a35f5c3b608b112f6d72dc381f0815f1751088410cdd8e44cd0e514cf628e2c31a746a58fdb2e6476f5c3f31ebf1e21b45a196b4f27bf65af48a1ff418d47"
    },
    {
      "line": 161,
      "relation": "increases",
      "evidence": "This effect has been shown to be mediated in part by heme-mediated degranulation of Weibel–Palade bodies (WPB), as demonstrated in vitro using human endothelial cells (HUVEC).",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 6,
      "key": "48f67fae2aa135064ee8235ac75594a8e0544ad61b7fdf24fdd99b468d3328453ebf5744bfde191272aae6f9d800ae19d9e10cf7a7a8ab970589755141dc0ea6"
    },
    {
      "line": 166,
      "relation": "increases",
      "evidence": "Moreover, in vitro studies have demonstrated that heme binds to human platelets and induces platelet activation and aggregation [37–39].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 22,
      "key": "d77946eb5e16f478f40aa2212f53cc163621caaa78e9b90c2d820bc76e5297a85c535b82bde3bbd8e5424abf9d812197017ee2369c55a8fe9e646c47d4c20d51"
    },
    {
      "line": 167,
      "relation": "increases",
      "evidence": "Moreover, in vitro studies have demonstrated that heme binds to human platelets and induces platelet activation and aggregation [37–39].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 27,
      "key": "7d799378020fcff827891d843833e4cad22c7934692b939d7fd9ccbf8a591fe5c74666afdda202ee618d14813e2e9a2f6f7b3b03f859347ee956bb86008e70de"
    },
    {
      "line": 172,
      "relation": "decreases",
      "evidence": "Heme significantly reduced FVIII cofactor activity by inhibiting its interaction with activated factor IX(FIXa) in vitro.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 0,
      "target": 44,
      "key": "dea833376276f7cbbed9c39fcefb8b56d1ca26f9eed8ee8034fa55c6100321c5507512df7fee153c5ecb31cbc223041010b2bb4ede0c315df199520de5b2e430"
    },
    {
      "line": 218,
      "relation": "decreases",
      "evidence": "Taken sequentially, it appears that the release of heme under hemolytic conditions initiates the extrinsic pathway of coagulation through the upregulation of TF on endothelial cells and leukocytes, but subsequently blocks the propagation of coagulation by inhibiting FVIII and FV, and by inhibiting the conversion of fibrinogen into fibrin and fibrin clots.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 44,
      "key": "8e52064aa12dbc0c859eab956d25ebc7deaee24b31caa5daef4baf6ada0643f443186eb15511524689f7b73adace970171f9fc777812baf0ca7339a9da33e803"
    },
    {
      "line": 185,
      "relation": "decreases",
      "evidence": "From another perspective, in vitro assays have demonstrated that heme can also bind to fibrinogen and decrease its thrombin-mediated cleavage, thus affecting the final common coagulation pathway and reducing fibrin formation, important in clotting [44] (Figure 1).",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 14,
      "key": "a12fe7227a66592ae406151bfd72a0e525b98306bd4c9d96ad35d22503e9c98c0ff80365376dc33801c7b133b8b5e23d17e85873468543f9c0aa98ab6ebc77b1"
    },
    {
      "line": 192,
      "relation": "decreases",
      "evidence": "Heme perturbs the enzymatic activity of thrombin, further contributing to the overall anticoagulant effect and decreased fibrin formation [45].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 14,
      "key": "cb137f3993184c44ad937247b88fa0479a5fe4a1acb511147e007941fdfecb496499b64feace26864d091a7de17ed893fa667934efd16c1ec8572be249137517"
    },
    {
      "line": 220,
      "relation": "decreases",
      "evidence": "Taken sequentially, it appears that the release of heme under hemolytic conditions initiates the extrinsic pathway of coagulation through the upregulation of TF on endothelial cells and leukocytes, but subsequently blocks the propagation of coagulation by inhibiting FVIII and FV, and by inhibiting the conversion of fibrinogen into fibrin and fibrin clots.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 14,
      "key": "f96b5072fe148553689d5d77d5a00f90ff55daf41410ed897a441feba1d5e473b3a9feb40bbd3c21b963f38263b76b3fbdb45a72a736a98c051f10f8e419a019"
    },
    {
      "line": 199,
      "relation": "increases",
      "evidence": "In contrast to the anticoagulant effect of heme on the intrinsic and terminal pathways of coagulation, heme can also trigger the extrinsic pathway of coagulation by upregulating tissue factor (TF) on the surface of human endothelial cells in vitro, as well as on leukocytes and perivascular cells in mice [50,51].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 54,
      "key": "27e8e6333acb0b4d582bc34d27ac4d3f608486e443b3c26e81541ce82cdaed4c076b402cca1b69d14acf1a581a8eb9af6ec1808405a9084dd0808b386ef3aadf"
    },
    {
      "line": 216,
      "relation": "positiveCorrelation",
      "evidence": "Taken sequentially, it appears that the release of heme under hemolytic conditions initiates the extrinsic pathway of coagulation through the upregulation of TF on endothelial cells and leukocytes, but subsequently blocks the propagation of coagulation by inhibiting FVIII and FV, and by inhibiting the conversion of fibrinogen into fibrin and fibrin clots.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 16,
      "key": "ec49bcca783814ea020509b71d2d1d4b35ac72c9d75e0cc38aae3e02794e5ece83186a1118e437aa3087968b9aeb277dbdb7483b784c6edcfc2920f828c7fab0"
    },
    {
      "line": 217,
      "relation": "increases",
      "evidence": "Taken sequentially, it appears that the release of heme under hemolytic conditions initiates the extrinsic pathway of coagulation through the upregulation of TF on endothelial cells and leukocytes, but subsequently blocks the propagation of coagulation by inhibiting FVIII and FV, and by inhibiting the conversion of fibrinogen into fibrin and fibrin clots.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 52,
      "key": "9ac083c44dc8919378ca19a2b288128ab3529d785a1fba223e4d31f7220873e9798742712ba4a61954a1bccb008a232cdf822ee0b2bbd9a13f876056642babbd"
    },
    {
      "line": 219,
      "relation": "decreases",
      "evidence": "Taken sequentially, it appears that the release of heme under hemolytic conditions initiates the extrinsic pathway of coagulation through the upregulation of TF on endothelial cells and leukocytes, but subsequently blocks the propagation of coagulation by inhibiting FVIII and FV, and by inhibiting the conversion of fibrinogen into fibrin and fibrin clots.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 42,
      "key": "762da184511bf4588dc5c787aad12386e60bb5ef96a96c06e1ec453fa42bcec78fa58f39c95cd28f81ee79619ca134fb0d6dc703a57cc009c6133aef69664f76"
    },
    {
      "line": 227,
      "relation": "negativeCorrelation",
      "evidence": "For example, the in vitro appearance of strong reactivity towards phospholipids of antibodies from normal human plasma following exposure to heme suggests that heme, when released in vivo, may perturb coagulation processes indirectly via its effects on antibodies.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 23,
      "key": "8770b9487506da05b99225d26c641bb3972449c5e1614ceed201d4df13ce382a4139ec678c29ab9fe5162f35660286aed4226e94fb92d281c2025ca3c3772f2d"
    },
    {
      "line": 233,
      "relation": "increases",
      "evidence": "Hemolytic diseases are often accompanied by dysregulation and overactivation of the complement system [72–74], which may be induced by free extracellular heme [33,75–77] (Figure 3B).",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 17,
      "key": "ee7bc49ffcb4b0cc490ad7c75ec456dd0ae740dab9722a2271c64a4a91b1c4f2984dd2d1d21a472be24501534b1e09e2d7af3d51d5405693495b0e3011cc5bba"
    },
    {
      "line": 319,
      "relation": "increases",
      "evidence": "Moreover, exposure of endothelial cells to heme results in diminished surface expression of the negative complement regulators decay-accelerating factor (DAF) and membrane cofactor protein (MCP) [33], and hence reduces protection against complement.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        }
      },
      "source": 0,
      "target": 17,
      "key": "b0ccb067f4bca24b20ea2e6e45f673afbc5126b34cd41d2340add04889f57a2695a79367370ab182bf5c0d444cd6ff4e65afe5ed2b0e766b168f820c8c7d6268"
    },
    {
      "line": 240,
      "relation": "increases",
      "evidence": "C3a and C5a anaphylatoxins, as well as the soluble membrane attack complex (sC5b9), are generated by incubation of heme with human serum or blood in vitro, via the alternative complement pathway [33,77] (Box 5).",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 10,
      "key": "bd36918de66fdd54501c45cade0cc8750e87bdee220c2e6c2657a78d51a7d27aa97487277fb6ab4e374f64d5e7f5f0c5bee1c57720ba3aa4cc63a8615b3a61c9"
    },
    {
      "line": 241,
      "relation": "increases",
      "evidence": "C3a and C5a anaphylatoxins, as well as the soluble membrane attack complex (sC5b9), are generated by incubation of heme with human serum or blood in vitro, via the alternative complement pathway [33,77] (Box 5).",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 11,
      "key": "814060490b804aced47473ff3cc3206f1cd9454e27669b928c8dba7edef8c6cd21aed38c06184f982084fcbf677385d9e965c0603e4e467d5de4377c1f2e893c"
    },
    {
      "line": 242,
      "relation": "increases",
      "evidence": "C3a and C5a anaphylatoxins, as well as the soluble membrane attack complex (sC5b9), are generated by incubation of heme with human serum or blood in vitro, via the alternative complement pathway [33,77] (Box 5).",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 0,
      "target": 12,
      "key": "d8831db48cf3b15ec72c04fa00d3d881d1918d5a5d7dda88fb410f988dec9365f02334847a6b19ba6dc660423ba9aed239238152436673cde287e520e375d90e"
    },
    {
      "line": 249,
      "relation": "increases",
      "evidence": "Furthermore, the incubation of serum or whole blood with heme induces deposition of activation fragments (C3b, iC3b, C3dg) of complement component 3 (C3) at the surface of erythrocytes [77].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 0,
      "target": 3,
      "key": "d7eeb6543dedccfea833936ea0b9e114574f0d26fe6b642a0c8d2dc399f04022c8cef0b688a1d0685cc94951046e83cd85f75e1c496d765d372d0f4ef958beb2"
    },
    {
      "line": 250,
      "relation": "increases",
      "evidence": "Furthermore, the incubation of serum or whole blood with heme induces deposition of activation fragments (C3b, iC3b, C3dg) of complement component 3 (C3) at the surface of erythrocytes [77].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 0,
      "target": 5,
      "key": "5b5173387352438d84bbb1b4e7558e84cb88327433f7a4fb413e87f37dae4b4cedd568f9ff0ef6dd6eda2bb513c3be85c991f46273806ed0b04fc1d2aa086ddd"
    },
    {
      "line": 251,
      "relation": "increases",
      "evidence": "Furthermore, the incubation of serum or whole blood with heme induces deposition of activation fragments (C3b, iC3b, C3dg) of complement component 3 (C3) at the surface of erythrocytes [77].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 0,
      "target": 4,
      "key": "0f1b629b3b3ed6528a720f9d33be76fe69a144d28fe7c43f96191503d4aa1932ef0dab91f74f623a7d4cda36a5754d35c60e28197284b67b60ccabc64c1f86a6"
    },
    {
      "line": 276,
      "relation": "increases",
      "evidence": "It is possible that heme-induced overactivation of the alternative complement pathway, and depo- sition of C3 fragments on erythrocyte membranes, participate in erythrophagocytosis of uninfected red blood cells in severe forms of malaria [77].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 0,
      "target": 18,
      "key": "62f559da3df6b00dcd3382d8c23f2d301b1f5e6587c042bf2a11dccff17cc4abb16a1754c1697f6ca8bd316a8b5b18800fc51cca2cabc1ecd0c32d8ede23d05c"
    },
    {
      "line": 302,
      "relation": "increases",
      "evidence": "Heme exposure of other proteins in the alternative pathway (factors B, D, and H) does not appear to have any impact on their functions, thus implying that heme activates the alternative complement pathway by affecting C3 directly [33].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 0,
      "target": 18,
      "key": "aa3d581b0f63b27e1f6c96dba4682390ae0459b44a705ab0896d627cbffe20498de5ef526fa879fae22fdbbeadbdb37a1527be104bad2440adad5f1df5ddf859"
    },
    {
      "line": 338,
      "relation": "increases",
      "evidence": "The inhibitory effect of heme on the classical pathway is in agreement with in vitro functional assays showing that heme is capable of activating only the alternative pathway in human sera.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        },
        "MeSHAnatomy": {
          "Serum": true
        }
      },
      "source": 0,
      "target": 18,
      "key": "10fc98de9d43e26af3c36afa7fe404bb1bf7fa93d267326e3617e250344de4ac41cb23f71eee69c64fdb50c946fa821a122cbf9c1c6f7ecb36d11b6541372c2d"
    },
    {
      "line": 345,
      "relation": "increases",
      "evidence": "In contrast to its overactivating effects on the alternative pathway, heme inhibits the classical pathway. It binds to C1q, alters its electrostatic properties, and hampers the recognition of target molecules. This results in a reduction of classical pathway C3 convertase formation and C3b deposition.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        },
        "MeSHAnatomy": {
          "Serum": true
        }
      },
      "source": 0,
      "target": 18,
      "key": "f6217c179d40201cb80419134ae09c2517284b7d5a353c54b211517a238e06feda724fd6250d40e625252b18ef8d91f956719346898f53afdb0ed252e3b0f697"
    },
    {
      "line": 298,
      "relation": "causesNoChange",
      "evidence": "Heme exposure of other proteins in the alternative pathway (factors B, D, and H) does not appear to have any impact on their functions, thus implying that heme activates the alternative complement pathway by affecting C3 directly [33].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 0,
      "target": 37,
      "key": "1a63ccc6c93bc2cb4d357085c10891b8c5810c0f31f0c52799e591c923d24602660e191e6f871f5374889c03a4829fed1611bf2bba590a9194432e7794290671"
    },
    {
      "line": 299,
      "relation": "causesNoChange",
      "evidence": "Heme exposure of other proteins in the alternative pathway (factors B, D, and H) does not appear to have any impact on their functions, thus implying that heme activates the alternative complement pathway by affecting C3 directly [33].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 0,
      "target": 38,
      "key": "a6c90c73972a6abc7415f49a6af4380760fc51af17598c109fdc3015a1b943ae1b14a08e67a41efb2dc985b38acb5468319aec924797e07d06f26433ca897a24"
    },
    {
      "line": 300,
      "relation": "causesNoChange",
      "evidence": "Heme exposure of other proteins in the alternative pathway (factors B, D, and H) does not appear to have any impact on their functions, thus implying that heme activates the alternative complement pathway by affecting C3 directly [33].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 0,
      "target": 39,
      "key": "6b43e66c7152f686bdb4ae46ebc322a407e2192e1ee2b67bb48640368a91ed462856f69dfe4a1bc2aa6d4079be7d453a137feb9b9aa3805a65e2e824d43a200f"
    },
    {
      "line": 301,
      "relation": "directlyIncreases",
      "evidence": "Heme exposure of other proteins in the alternative pathway (factors B, D, and H) does not appear to have any impact on their functions, thus implying that heme activates the alternative complement pathway by affecting C3 directly [33].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 0,
      "target": 33,
      "key": "8bbaedb28a8ae4e1fa08436bf09585c5138e3b71a9ee027a96941b57642ccf0e07903454f1ebbfa724618e1eb86cf0599bfa22060e3b89564e248a05113b049d"
    },
    {
      "line": 317,
      "relation": "decreases",
      "evidence": "Moreover, exposure of endothelial cells to heme results in diminished surface expression of the negative complement regulators decay-accelerating factor (DAF) and membrane cofactor protein (MCP) [33], and hence reduces protection against complement.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        }
      },
      "source": 0,
      "target": 35,
      "key": "3268ee723e39153933f01f53f071867067cd2d280699e4544932f0932ffaa52deeab74d57959596e4396104291973dc50722fac5ec569e7d5da94a2c7f275abf"
    },
    {
      "line": 318,
      "relation": "decreases",
      "evidence": "Moreover, exposure of endothelial cells to heme results in diminished surface expression of the negative complement regulators decay-accelerating factor (DAF) and membrane cofactor protein (MCP) [33], and hence reduces protection against complement.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        }
      },
      "source": 0,
      "target": 34,
      "key": "26a731d72eb11f4c67ad9418b77fcb6d13d92969421942fa94d908be03ab586934079d286399a4bcb13b76fc15b78adbec2a0e6936dd99716b077536c558c824"
    },
    {
      "line": 330,
      "relation": "decreases",
      "evidence": "Heme could suppress C1q binding to its main ligands, immunoglobulins and C-reactive protein (CRP), in a concentrationdepended manner.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 0,
      "target": 55,
      "key": "05e1f5ec658e1914f8dac54b278d60ba93c617373f43ab597fd0ec48ed8c7933242c472020a5bc50127ccef4a00bc5681c7b8c0980fd87f59b0d6c105b5e0158"
    },
    {
      "line": 346,
      "relation": "decreases",
      "evidence": "In contrast to its overactivating effects on the alternative pathway, heme inhibits the classical pathway. It binds to C1q, alters its electrostatic properties, and hampers the recognition of target molecules. This results in a reduction of classical pathway C3 convertase formation and C3b deposition.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        },
        "MeSHAnatomy": {
          "Serum": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 0,
      "target": 55,
      "key": "6a24b65e20003fab7762074897635d2bab77e40a15aab08263a1f01b6ec62c5ab8f68fb15dc51e95103ce64614e92199d1ea633fef8aa49132d2139ced4ed814"
    },
    {
      "line": 337,
      "relation": "decreases",
      "evidence": "The inhibitory effect of heme on the classical pathway is in agreement with in vitro functional assays showing that heme is capable of activating only the alternative pathway in human sera.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        },
        "MeSHAnatomy": {
          "Serum": true
        }
      },
      "source": 0,
      "target": 19,
      "key": "c9daa4aba8c259b5dd4e6088c1cdfbb0e38c7a9358550557ef136337293c0f48badb6c10c0f75bca02c5180a8478a43808387a5669f831fd21d0a87f26ab0cbf"
    },
    {
      "line": 344,
      "relation": "decreases",
      "evidence": "In contrast to its overactivating effects on the alternative pathway, heme inhibits the classical pathway. It binds to C1q, alters its electrostatic properties, and hampers the recognition of target molecules. This results in a reduction of classical pathway C3 convertase formation and C3b deposition.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        },
        "MeSHAnatomy": {
          "Serum": true
        }
      },
      "source": 0,
      "target": 19,
      "key": "1a75636de43b7ef627ceb8210c7fcd19b8f26e8ecbaa8678cd04323d3f5882c1d1ec0588b532e743d2ef98179ed374d3213b9f11d973716af21b30b1ec2966e4"
    },
    {
      "line": 355,
      "relation": "increases",
      "evidence": "Heme may be implicated and contribute to the development of (i) thrombotic microangiopthy in patients with aHUS [33], (ii) vaso-occlusion in sickle-cell disease [18,24,27,32], (iii) vascular injury and kidney dysfunction in transfusion of old blood [16], (iv) atherosclerosis [92], or (v) erythrocyte loss in malaria [77].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Atypical Hemolytic Uremic Syndrome": true
        },
        "Cell": {
          "endothelial cell": true
        },
        "MeSHAnatomy": {
          "Serum": true
        }
      },
      "source": 0,
      "target": 56,
      "key": "eb2ffd8dc851dda00245c8e664bdc253ff4269b37dbef012e57431a0695c4ba3a6e0e04425ba8d0fdf58577afee740bdfece34a82b6c4443c78922ced8fd9e75"
    },
    {
      "line": 359,
      "relation": "increases",
      "evidence": "Heme may be implicated and contribute to the development of (i) thrombotic microangiopthy in patients with aHUS [33], (ii) vaso-occlusion in sickle-cell disease [18,24,27,32], (iii) vascular injury and kidney dysfunction in transfusion of old blood [16], (iv) atherosclerosis [92], or (v) erythrocyte loss in malaria [77].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        },
        "Cell": {
          "endothelial cell": true
        },
        "MeSHAnatomy": {
          "Serum": true
        }
      },
      "source": 0,
      "target": 60,
      "key": "d4622a6b7b154fe7ee48ae28af847744b07effb617f9212fc1d93b175c20c6c0f546fc4e6d57172e2647dc9dd9e81b6f9c906b1844089d98e2c0e15afef79b3c"
    },
    {
      "line": 360,
      "relation": "increases",
      "evidence": "Heme may be implicated and contribute to the development of (i) thrombotic microangiopthy in patients with aHUS [33], (ii) vaso-occlusion in sickle-cell disease [18,24,27,32], (iii) vascular injury and kidney dysfunction in transfusion of old blood [16], (iv) atherosclerosis [92], or (v) erythrocyte loss in malaria [77].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        },
        "Cell": {
          "endothelial cell": true
        },
        "MeSHAnatomy": {
          "Serum": true
        }
      },
      "source": 0,
      "target": 59,
      "key": "70a98fa8a60b2e59216ad61d074f1c7e3a4e2d1e124b47b2970d1f82050b40233926712c30fb634e79c44ff7296ebfd5ea454842af624d75b97883e665ffdaff"
    },
    {
      "line": 362,
      "relation": "increases",
      "evidence": "Heme may be implicated and contribute to the development of (i) thrombotic microangiopthy in patients with aHUS [33], (ii) vaso-occlusion in sickle-cell disease [18,24,27,32], (iii) vascular injury and kidney dysfunction in transfusion of old blood [16], (iv) atherosclerosis [92], or (v) erythrocyte loss in malaria [77].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        },
        "Cell": {
          "endothelial cell": true
        },
        "MeSHAnatomy": {
          "Serum": true
        }
      },
      "source": 0,
      "target": 61,
      "key": "2e8a00ba9a84410bf69be5423b86556b88208ba7aef15c136071d8e8bf5aadac164ddc7e97edc7031cb9e7a2e351fff6d018125f14765cff4d162788f5406962"
    },
    {
      "line": 365,
      "relation": "decreases",
      "evidence": "Heme may be implicated and contribute to the development of (i) thrombotic microangiopthy in patients with aHUS [33], (ii) vaso-occlusion in sickle-cell disease [18,24,27,32], (iii) vascular injury and kidney dysfunction in transfusion of old blood [16], (iv) atherosclerosis [92], or (v) erythrocyte loss in malaria [77].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        },
        "MeSHAnatomy": {
          "Serum": true
        }
      },
      "source": 0,
      "target": 24,
      "key": "8c3e55f90952c4f43da46f9f556853df5210700ed84e6376425766df0d3b2f7b8b652409ee019ed67043211ddffbc61c038e7a8cc941c6061ea629ecb178c9f6"
    },
    {
      "line": 370,
      "relation": "increases",
      "evidence": "Despite its damaging effects, heme induces the expression of HO-1, which degrades heme to anti-inflammatory, cytoprotective, and antioxidant products [25].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        },
        "MeSHAnatomy": {
          "Serum": true
        }
      },
      "source": 0,
      "target": 46,
      "key": "028d4091c29e5287ae1266e88ec8aa2dc55523a5b6643f5e261c126c2740d28ec0311b83115dbe3fd671e178f0eb7bd7712825074a48749bdf77c952e44ce93c"
    },
    {
      "line": 109,
      "relation": "decreases",
      "evidence": "Thus, the interactions of hemoglobin with haptoglobin, and of heme with hemopexin, ensure safe disposal of potentially dangerous molecules [6,7,15–19]",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 47,
      "target": 45,
      "key": "7542121157fbc9291c6e3ca754d83aaaead62bda93e3185363fb932751d6e0e167b89ff35b649c96a2697da19bce637633d4cf9f63a934f1c39b39c94a8ed0b2"
    },
    {
      "line": 115,
      "relation": "negativeCorrelation",
      "evidence": "In cases of extensive and chronic hemolysis, levels of haptoglobin and hemopexin in plasma decrease markedly [20,21].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 47,
      "target": 62,
      "key": "9fcaa42c2164421011468063ccd90980fc88f9e99b5a68839aca33eb543b03694876adb735c44b314079578e0afc300069dee821514a85449f3d79da04412e74"
    },
    {
      "line": 110,
      "relation": "decreases",
      "evidence": "Thus, the interactions of hemoglobin with haptoglobin, and of heme with hemopexin, ensure safe disposal of potentially dangerous molecules [6,7,15–19]",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 48,
      "target": 0,
      "key": "b39b0b14dd131435d2918fb5f7d93bfa2051b647286862b8383fccd9c5ab1a15f6ed2c956d45f1d9ec8499cfa5fc3185a68699bb0c020bab43cf740251efe103"
    },
    {
      "line": 116,
      "relation": "negativeCorrelation",
      "evidence": "In cases of extensive and chronic hemolysis, levels of haptoglobin and hemopexin in plasma decrease markedly [20,21].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 48,
      "target": 62,
      "key": "4511723cd9b29cca0c6421097da8006d60461345f3b17bfbbd022d4159d0590f7d50385f8b44c441c5a8d92287f35bce3c571e7e26cb96efd7587cc19fac0f45"
    },
    {
      "line": 115,
      "relation": "negativeCorrelation",
      "evidence": "In cases of extensive and chronic hemolysis, levels of haptoglobin and hemopexin in plasma decrease markedly [20,21].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 62,
      "target": 47,
      "key": "70c8364d95f182ee4a7f7cc3b9ec8ba8e7dfddcc1e68e63655ac11ceadff32baa1f7f1bb101ef59a7c7eeaf0b66df3c3dc6d6352ec73d9204452d151d11c0276"
    },
    {
      "line": 116,
      "relation": "negativeCorrelation",
      "evidence": "In cases of extensive and chronic hemolysis, levels of haptoglobin and hemopexin in plasma decrease markedly [20,21].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 62,
      "target": 48,
      "key": "db7ba2c247de741d30d07304f481b0504bcf8e4be1a851b9628d74130243dd6a9930e53934223c1a017708e863319c0a9d12454da1a8c37fd27f077dd247b8b9"
    },
    {
      "line": 130,
      "relation": "increases",
      "evidence": "Interestingly, a recent study demonstrated that, in severe hemolytic disease (sickle cell anemia), at least one third of plasma heme was associated with membrane vesicle structures (microparticles) that were generated from erythrocytes during hemolysis [24].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 62,
      "target": 9,
      "key": "79d9b68ce669bed8d08036c15b10918ba621ac71eef1be4de1051bed984aebf014fafdf3e82c9eb66741a8b0a0a5c4106339aca338e0a722983ae8ce5e92712c"
    },
    {
      "line": 124,
      "relation": "decreases",
      "evidence": "Excess extracellular heme is weakly bound to albumin [22], /1-microglobulin (which can also degrade heme) [23] and, most likely, to other plasma proteins and lipoproteins; there is a dynamic nature to such interactions.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 32,
      "target": 0,
      "key": "0ce64aa8096657103c2195366be43acba1d7d7a6959b42253046bed7d6929ea52ee0b355e6d92562a03e1c9d8be4ac8fecd1cf77c6523e3cef54f792a7c8e687"
    },
    {
      "line": 131,
      "relation": "increases",
      "evidence": "Interestingly, a recent study demonstrated that, in severe hemolytic disease (sickle cell anemia), at least one third of plasma heme was associated with membrane vesicle structures (microparticles) that were generated from erythrocytes during hemolysis [24].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        }
      },
      "source": 28,
      "target": 9,
      "key": "7fa4ab9620c9eee74849fdbbf3ed9a266344837797fcbdb5721a8f098411316690f4f090acbd9f1fc21b9d7949837d2b87e5379bee1fdcc0b41947a19a3de78f"
    },
    {
      "line": 178,
      "relation": "decreases",
      "evidence": "In humans and mice, VWF protects FVIII from degradation by proteases in the circulation and controls FVIII catabolism [43].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 53,
      "target": 44,
      "key": "4f2bfbb62a81edfc628c406082914b142fc5d1780297d5155e8225f549823d69ebcc74bc3b44004aa3833a5744a817dfc679078e402c4d7c1c909a57fec8715c"
    },
    {
      "relation": "hasComponent",
      "source": 31,
      "target": 41,
      "key": "b63a148f6666e26245d05eff1188bf78a408875a95bc19696ea9d46556ee5a033a0484fb3bec8cc97678a7c7a52746e75ab105feb13fde4f039d4a6261603b00"
    },
    {
      "relation": "hasComponent",
      "source": 31,
      "target": 43,
      "key": "225a619f3106e01bbc8dba5e9eb25ae3de9568eaad0c56436e650e14b2cf44c7bebdf7c8bc9209bd94c5e0fac33d56787853da629fb92f10727049d7a5b6a0e9"
    },
    {
      "line": 205,
      "relation": "increases",
      "evidence": "In the extrinsic pathway of coagulation, upregulated TF binds to activated factor VII (FVIIa), thus leading to activation of FX.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 31,
      "target": 40,
      "key": "0be62e976d03f629c6b369da5ee8e8039091db421a6c22f056a9a167bd5d991d6828aac6b640c92affbcacf5cdd10ae03b7d02fef4fe82519a1143f28356a2ed"
    },
    {
      "line": 216,
      "relation": "positiveCorrelation",
      "evidence": "Taken sequentially, it appears that the release of heme under hemolytic conditions initiates the extrinsic pathway of coagulation through the upregulation of TF on endothelial cells and leukocytes, but subsequently blocks the propagation of coagulation by inhibiting FVIII and FV, and by inhibiting the conversion of fibrinogen into fibrin and fibrin clots.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 16,
      "target": 0,
      "key": "8bdb74534a18b9a418d23aa03cda73e928c5c3d03e0428ad121780a62cece1a421ac489e30f41867c22618d64e8bd74f6a7f4911e07f685f842513f21ff7cdbb"
    },
    {
      "line": 227,
      "relation": "negativeCorrelation",
      "evidence": "For example, the in vitro appearance of strong reactivity towards phospholipids of antibodies from normal human plasma following exposure to heme suggests that heme, when released in vivo, may perturb coagulation processes indirectly via its effects on antibodies.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        }
      },
      "source": 23,
      "target": 0,
      "key": "5ecac8b070ef3a0be790d8fd6e32ebd36e15257d81f18f87b9fbdd2af9c92c51e8d08bac6c59f18050b39a2db2ae438f69a728f67198bb7a4c4fe606bff48173"
    },
    {
      "line": 255,
      "relation": "association",
      "evidence": "Indeed, the severe forms of malaria are associated with activation of the complement system [74].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 17,
      "target": 64,
      "key": "d53809559566612ffa7d68434a920ea31769d9f1035ed2f1276c93728d5d88cf4b58351e2c0a1ebdf59775d01cffd6a0346febf93dc85892f52336e9a1a91bdc"
    },
    {
      "line": 255,
      "relation": "association",
      "evidence": "Indeed, the severe forms of malaria are associated with activation of the complement system [74].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 64,
      "target": 17,
      "key": "d20d5c88f3511407e9cb447ebbc921ea78b8125a47ab7932133d60f720d6f640e3e201821f4eadf082bf97184464ff1b78a386ac2c5662a1b012cbdf0dd206bc"
    },
    {
      "line": 260,
      "relation": "increases",
      "evidence": "Plasmodium-mediated lysis of a single infected erythrocyte in vivo was shown to result in the lysis of 8–10 uninfected cells [78,79].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "subject": {
        "modifier": "Activity"
      },
      "source": 15,
      "target": 62,
      "key": "e7bf7ff41cf357806f080efda8782624b3d0d915075b7b59f7771c9f552d26688bcf9b00f2560b6b02ca1eb93e3a66140e5910e851fb0be1e19a33a5db8fee96"
    },
    {
      "line": 266,
      "relation": "positiveCorrelation",
      "evidence": "The mechanism behind this erythrocyte loss is not well understood but may be related to reduced erythrocyte deformability, accelerated senescence, or to complement or antibody-mediated (anti-erythrocyte) erythrophagocytosis [79].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 25,
      "target": 24,
      "key": "abdbdf979724f75f9015cf55f85c27b4f3cc2f2d1ca71b55809cc194ea586e1628e1cde4870e3518a1db9db5754090f9a75cfa41e53f20c6f04c564fe720c645"
    },
    {
      "line": 266,
      "relation": "positiveCorrelation",
      "evidence": "The mechanism behind this erythrocyte loss is not well understood but may be related to reduced erythrocyte deformability, accelerated senescence, or to complement or antibody-mediated (anti-erythrocyte) erythrophagocytosis [79].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 24,
      "target": 25,
      "key": "b440c9bd6de0e92559f821b5d0981b62e983c9e19a3e9f074a0928f87b59695311c4e7bd8a88aa9103e185e0107accd5ec19241ae780a6879f3d3fb770233eb0"
    },
    {
      "line": 267,
      "relation": "decreases",
      "evidence": "The mechanism behind this erythrocyte loss is not well understood but may be related to reduced erythrocyte deformability, accelerated senescence, or to complement or antibody-mediated (anti-erythrocyte) erythrophagocytosis [79].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Anemia, Sickle Cell": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 8,
      "target": 24,
      "key": "43f717a8b8f21135202ad875c32d652f9e846df9feaf8730815ad7a7c7c1c22caa03a29c248b8c225dd0685aa4d1703b35b75bf8e7375377a5c97d4e9bdc2f22"
    },
    {
      "line": 277,
      "relation": "positiveCorrelation",
      "evidence": "It is possible that heme-induced overactivation of the alternative complement pathway, and depo- sition of C3 fragments on erythrocyte membranes, participate in erythrophagocytosis of uninfected red blood cells in severe forms of malaria [77].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 8,
      "target": 18,
      "key": "585132844b7e57719d1c97a004d0cd68035107aee00dca7c9cbdda15006ca21b1df9d241d0b38cda2bfcacb838f80eeecbce1378c4e92cf32ff1fc6bb19c8ebf"
    },
    {
      "line": 277,
      "relation": "positiveCorrelation",
      "evidence": "It is possible that heme-induced overactivation of the alternative complement pathway, and depo- sition of C3 fragments on erythrocyte membranes, participate in erythrophagocytosis of uninfected red blood cells in severe forms of malaria [77].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 18,
      "target": 8,
      "key": "a93d6fdac77e23ddf5ca6615969c81de493ab38c0b81d31ae063ae3f5f83220352cf3a2df00a168fb2e9527b1618539ca920c12a997fd21068fab239e03910a3"
    },
    {
      "line": 286,
      "relation": "decreases",
      "evidence": "This scenario may resemble that of paroxysmal nocturnal hemoglobinuria patients, who can be treated with complement C5- blocking antibody eculizumab [80]; in this example, extravascular hemolysis has been shown to occur in a small number of these patients despite treatment. It has been suggested that this is due to erythrophagocytosis of red blood cells deficient in the C3d-opsonized complement regulators – CD55 and CD59 [81,82].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 35,
      "target": 62,
      "key": "27cb98b28c18b364e3407e35abcb86b4f94e9d39eab4ff51c9123aba19592600c6904f3c88129f56194627994916615096a7c295348350bfcdb6501a5328a99b"
    },
    {
      "line": 287,
      "relation": "decreases",
      "evidence": "This scenario may resemble that of paroxysmal nocturnal hemoglobinuria patients, who can be treated with complement C5- blocking antibody eculizumab [80]; in this example, extravascular hemolysis has been shown to occur in a small number of these patients despite treatment. It has been suggested that this is due to erythrophagocytosis of red blood cells deficient in the C3d-opsonized complement regulators – CD55 and CD59 [81,82].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 36,
      "target": 62,
      "key": "9cc48ac93d249fb97f0724f193b18712c1dd42dc75a0705e0a1790db7dca181d8e42c1e2ad86c7f518a6f92d2ec8bc674a83b45e16c785d05b3cb3dc6d13192b"
    },
    {
      "relation": "hasComponent",
      "source": 29,
      "target": 0,
      "key": "65100205e9c7fa3ce3eba80d5d84e1fe4e582a86c304670d2f4cb31601fe56b7547575d8b9a100e723c569efb62dce3ce6055c44bae9b3cd1b9db81f56a46d22"
    },
    {
      "relation": "hasComponent",
      "source": 29,
      "target": 2,
      "key": "b2dd75871176ae0c4f26b00b12fe08df28ac341cf0554857d33a617f9ba9f0b0b60224167f013a9044e7271ff460fdef33dc000b82072f958717c5f376cb79c5"
    },
    {
      "line": 292,
      "relation": "increases",
      "evidence": "Molecular docking predicted the interaction of heme in close proximity to a thioester bond, known to be important for the activation of C3.",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "erythrocyte": true
        }
      },
      "source": 29,
      "target": 33,
      "key": "bc1717f4bdd8a26e90a85285a8fb4416ac2a34a038d29150e3047162aecf01666b64f7f3b1043a8f970caf2bde1f5349501ba4d9c974588188f5bf1070610c52"
    },
    {
      "line": 310,
      "relation": "increases",
      "evidence": "Deposition of C3 fragments on endothelial cells may be due to increased expression of P-selectin [33], serving as a platform for C3b deposition, as suggested by experiments using transfected cells and endothelial cells in vitro, as well as in a mouse model of Shiga toxin infection [84,85].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        }
      },
      "source": 50,
      "target": 3,
      "key": "fa86ed885ebae889dcedc881115d7b80969c2e2a490b392cbee34f37bbb2d1dac637b78432a61865588012033ba8fa290fbccd933b69f84a8a6c4f609d130cc8"
    },
    {
      "relation": "hasComponent",
      "source": 30,
      "target": 0,
      "key": "c6b955876dafc7daf371892a4be72b2ff1547b6477ee2a3324951a03064d475cd8eb31ab5cf9563de77d082447b794550053a872ff874b8798bce87c51abf8c2"
    },
    {
      "relation": "hasComponent",
      "source": 30,
      "target": 55,
      "key": "3a78351ac5b2d9a15cc4c1f75816b24156fd78d8683dc33ac5fc6b24f9e4b402537e817ded281628d48285f84b6f9b181ef7a94c2adbb180bb754f3d500a5530"
    },
    {
      "line": 324,
      "relation": "decreases",
      "evidence": "However, in contrast to its effect on C3, exposure of C1q to heme was demonstrated to inhibit its functions in vitro [89,90] (Figure 3B).",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        }
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 30,
      "target": 33,
      "key": "a802f3ae081cda8f9a82d22e1df8b5d60738110e7aaccf35a688edef1322cd4fe5b58b6a9bd27de2a18363c782530e0ec616258b1f4fee318adb52cddbac7485"
    },
    {
      "line": 371,
      "relation": "increases",
      "evidence": "Despite its damaging effects, heme induces the expression of HO-1, which degrades heme to anti-inflammatory, cytoprotective, and antioxidant products [25].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        },
        "MeSHAnatomy": {
          "Serum": true
        }
      },
      "object": {
        "modifier": "Degradation"
      },
      "source": 46,
      "target": 0,
      "key": "38b1c604ede22352c9a039ca811bd2b6a878f2868a5a9024f6ba504dc2c11df3e06a9c3313e7a143875ffa136e71d1074ab35dd9986d0beb85765631f0510acc"
    },
    {
      "line": 376,
      "relation": "increases",
      "evidence": "A recent Phase IIB clinical trial showed that preconditioning using hemin upregulated HO-1 in renal transplantation, launching further studies on clinical outcome [97].",
      "citation": {
        "type": "PubMed",
        "name": "Trends in molecular medicine",
        "reference": "26875449",
        "title": "Heme: Modulator of Plasma Systems in Hemolytic Diseases.",
        "volume": "22",
        "pages": "200-213",
        "date": "2016-03-01",
        "first": "Roumenina LT",
        "last": "Dimitrov JD",
        "authors": [
          "Dimitrov JD",
          "Lacroix-Desmazes S",
          "Rayes J",
          "Roumenina LT"
        ]
      },
      "annotations": {
        "TextLocation": {
          "Review": true
        },
        "MeSHDisease": {
          "Malaria": true
        },
        "Cell": {
          "endothelial cell": true
        },
        "MeSHAnatomy": {
          "Serum": true
        }
      },
      "source": 1,
      "target": 46,
      "key": "da0d2d639f4305a65ffa58b1e90f34bb05ccdb0057a301e605bb8342d0c38299bab6b1de7a8d3f2c9c34aa55b57042d526c3022270388414dd894ccc94629495"
    }
  ]
}